The benefit of MR-only radiotherapy treatment planning for anal and rectal cancers: A planning study

David Bird¹,²  Michael G. Nix¹  Hazel McCallum³,⁴  Mark Teo¹  
Alexandra Gilbert¹,²  Nathalie Casanova¹  Rachel Cooper¹  
David L. Buckley⁵  David Sebag-Montefiore¹,²  Richard Speight¹  
Bashar Al-Qaisieh¹  Ann M. Henry¹,²

¹ Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK  
² Radiotherapy Research Group, Leeds Institute of Medical Research, Leeds, UK  
³ Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK  
⁴ Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK  
⁵ Biomedical Imaging, University of Leeds, Leeds, United Kingdom

Correspondence  
David Bird, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.  
Email: David.Bird3@nhs.net

Funding information  
Cancer Research UK Centres Network Accelerator; Grant/Award Number: A21993; NIHR Research Trainees Coordinating Centre, Grant/Award Number: ICA-CDRF-2017-03-005

Abstract  
Introduction: Limited evidence exists showing the benefit of magnetic resonance (MR)-only radiotherapy treatment planning for anal and rectal cancers. This study aims to assess the impact of MR-only planning on target volumes (TVs) and treatment plan doses to organs at risks (OARs) for anal and rectal cancers versus a computed tomography (CT)-only pathway.

Materials and methods: Forty-six patients (29 rectum and 17 anus) undergoing preoperative or radical external beam radiotherapy received CT and T2 MR simulation. TV and OARs were delineated on CT and MR, and volumetric arc therapy treatment plans were optimized independently (53.2 Gy/28 fractions for anus, 45 Gy/25 fractions for rectum). Further treatment plans assessed gross tumor volume (GTV) dose escalation. Differences in TV volumes and OAR doses, in terms of Vx Gy (organ volume (%) receiving x dose (Gy)), were assessed.

Results: MR GTV and primary planning TV (PTV) volumes systematically reduced by 13 cc and 98 cc (anus) and 44 cc and 109 cc (rectum) respectively compared to CT volumes. Statistically significant OAR dose reductions versus CT were found for bladder and uterus (rectum) and bladder, penile bulb, and genitalia (anus). With GTV boosting, statistically significant dose reductions were found for sigmoid, small bowel, vagina, and penile bulb (rectum) and vagina (anus).

Conclusion: Our findings provide evidence that the introduction of MR (whether through MR-only or CT-MR pathways) to radiotherapy treatment planning for anal and rectal cancers has the potential to improve treatments. MR-related OAR dose reductions may translate into less treatment-related toxicity for patients or greater ability to dose escalate.

KEYWORDS  
MRI-only planning, MR-only

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2021 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, LLC on behalf of The American Association of Physicists in Medicine
1 | INTRODUCTION

Magnetic resonance imaging (MRI)-only radiotherapy treatment planning is the use of an MRI scan alone to plan radiotherapy treatments. These techniques require the generation of a "synthetic-computed tomography (CT)" (computer generated) dataset as MRI does not directly provide the patient density information required to allow dose calculation that is usually obtained from CT. MR-only planning techniques have developed considerably in recent years, with commercial synthetic-CT (sCT) solutions now available and specialist centers treating prostate cancers. However, a remaining challenge to wide-spread adoption is the lack of evidence within the literature demonstrating the impact of MR-only radiotherapy treatment planning to patients, in terms of improving treatments compared to standard pathways.

To the authors' knowledge, only one study has assessed the impact of MR-only radiotherapy treatment planning on patient outcomes; finding prostate treatment acute outcomes were similar to a CT-MR pathway. For anal and rectal cancers, there is no evidence in the literature quantifying the impact of MR-only radiotherapy treatment planning to patient treatments.

It is difficult to assess the impact of MR-only radiotherapy treatment planning as standard pathways in routine clinical use include CT-only or CT-MR pretreatment imaging. CT-only radiotherapy treatment planning pathways are common in many centers, for example in the UK, where dedicated radiotherapy MR provision is relatively scarce. However, where the MR simulation resources are available, CT-MR pathways are the preferred option. The central hypothesis for using MRI in the radiotherapy treatment planning process, whether in a CT-MR or MR-only pathway, is that the improved soft-tissue contrast of MR allows improved visualization of target volumes (TVs). For anal and rectal cancers, it is hypothesized this could lead to more accurate definition of tumors and therefore reduced radiotherapy TVs. This is supported by diagnostic anal and rectal study findings of net reductions in tumor volume when delineated on MR versus CT.

Comparing MR-only to CT-MR pathways, there are a number of benefits which include reduced CT scanning, streamlining clinical workflows, and removing CT-MR registration uncertainties. As well as the logistical and practical advantages, it is the removal of systematic CT-MR registration errors which could further improve patient treatments.

Here, we aim to quantify the impact of MR-only radiotherapy treatment planning on TVs and treatment plan OAR doses if TV coverage is maintained. By comparing MR-only and CT-only pathways, we are assessing both the benefit of including MR in the treatment pathway, which is also true of a CT-MR pathway and the benefit of removing CT-MR pathway registration uncertainties. We also hypothesize that gross tumor volume (GTV) dose escalation planning would enhance the benefit from MR-only versus CT-only planning due to the reduced volume of GTVs delineated on MR versus CT.

2 | METHODS

2.1 | Data collection

This study recruited 46 patients with anal and rectal cancer from a single center; 29 rectum and 17 anus; 24 male and 22 female, who were due to undergo preoperative or radical volumetric arc therapy (VMAT) external beam radiotherapy. Exclusion criteria included patients with contra-indications to MR. Patient demographics and staging can be seen in Appendix A, Table A1. This study is part of a wider MR-only radiotherapy study: “MR-only treatment planning for Anal and Rectal cancer radiotherapy” (MANTA-RAY), research ethics committee reference: 18/LO/1298, ISRCTN Registry: ISRCTN82734641.

All patients received CT and T2-SPACE MR simulation in the radiotherapy treatment position with matched bladder filling and immobilization protocols. CT and MRI scan parameters can be seen in Appendix A, Table A2. For MR simulation, coil bridges were used to prevent the coils from deforming the patient skin position. As MR simulation was for research purposes it was scheduled for a time when the patient had a clinical appointment, and the MR scanner was available. The mean time between planning CT and MR data acquisition was 15.1 days. The timings of the MR scans can be seen in Appendix A, Table A1, where in total 41% of MR scans were acquired prior to treatment starting, 69% were acquired by the end of week 1 of treatment (fraction 5), and 95% were acquired by the end of week 2 of treatment (fraction 10). MR scans were rigidly registered by an experienced clinical scientist specializing in image registration, focusing on the rectum and anal canal, to their paired CT datasets using the mutual information registration algorithm in Raystation 8b (RaySearch Laboratories, Stockholm, Sweden). MRs were resampled to the CT frame of reference using Raystation 8b’s standard tri-linear resampling. A synthetic-CT (sCT) scan was generated from each patient’s T2-SPACE MR scan using a deep learning-based cGAN sCT model. The cGAN sCT model and the CT and MR acquisition parameters have been previously described in the literature.
TABLE 1  Target volume delineations and their definitions for anal and rectal cancers, including gross tumor volume (GTV), nodal gross tumor volume (GTVN), boost gross tumor volume (GTVBoost), primary clinical target volume (CTVA), elective clinical target volume (CTVB/E), nodal clinical target volume (CTVN), final clinical target volume (CTVF), primary planning target volume (PTV/PTVA), nodal planning target volume (PTVN) and elective planning target volume (PTVE)

| Anus Target volume | Rectum Target volume | Definition |
|-------------------|---------------------|------------|
| GTV               | CTV                 | Macroscopic primary tumor only | CT: Macroscopic primary tumor extended to whole lumen and identified nodal tumorsMR: Macroscopic primary tumor only |
| CTVA              | CTVA                | T1/2: GTV + 1.0 cm enlarged to include the whole of the anal canal and external sphincters | CTVA GTV + 1.0 cm |
|                   | CTVB                | T3/4: GTV + 1.5 cm enlarged to include the whole of the anal canal and external sphincters | CTVB Elective anatomically defined volume including the mesorectum, pre-sacral, internal iliac and pelvic side-wall nodes |
| PTVA              | CTVF                | CTVA + 1.0 cm               | CTVA + CTVB |
| GTVBoost          | PTV                 | GTV + 0.5 cm               | CTVF + 1.5 cm (anterior) and 1 cm (all other directions) |
| GTVN              | PTV                 | Identified nodal tumors     | GTVBoost GTV + 1.0 cm |
| CTVN              | CTVE                | CTV + 0.5 cm               | X PTVN CTVE + 0.5 cm |
| PTVN              |                    | Elective anatomically defined volume including the mesorectal, bilateral inguinal, internal, and external iliac nodes to 2 cm above the lower border of sacroiliac joints, presacral nodes (or 1.5 cm superior from the most superior GTV) | CTVE Elective anatomically defined volume including the mesorectum, bilaterally defined the iliac, internal and external iliac nodes to 2 cm above the lower border of sacroiliac joints, presacral nodes (or 1.5 cm superior from the most superior GTV) |

2.2 TV and OAR delineation

All TVs (defined in Table 1) were delineated on CT and T2 MR simulation scans separately according to our center’s clinical protocol, apart from GTVBoost volumes which were chosen according to clinical trials assessing GTV dose escalation. All patients had diagnostic MR available, and patients with anal cancer additionally had diagnostic PET-CT available to assist delineations through side-by-side comparisons to the planning scan as per our center’s clinical protocol. These diagnostic scans were unsuitable for registration and further use in the study.

CT TVs, as used for each patient’s clinical treatment, were delineated by the treating consultant clinical oncologist. MR GTV delineations were undertaken by one of three consultant clinical oncologists specializing in anal and rectal cancer treatments with experience of interpreting T2 MR sequences for ano-rectal tumor delineations. MR GTVs were undertaken 2+ months after CT delineations to avoid potential recollection bias. All GTV delineations were undertaken using all clinically available information, apart from the other scan (CT or MRI). An experienced clinical scientist specializing in radiotherapy imaging created all other MR TVs through expansions and manual adjustments, all matching the CT clinical pathway (Table 1). For elective CTVs (rectum and anus), the CT CTV was rigidly transferred to the MR and manually adjusted to anatomical boundaries, accounting for anatomical changes between CT and MR, for example differences in the mesorectum boundary.

OARs were delineated on CT and MR by experienced dosimetrists and included bladder, small bowel, sigmoid, penile bulb, vagina, uterus (rectum and anus), bowel cavity (rectum only), femoral heads, and genitalia (anus only). All OARs were assessed and amended as required by an experienced clinical scientist to ensure accuracy. Genitalia OARs (delineated from anatomical landmarks) were delineated on CT and rigidly transferred to MR to ensure consistency. Penile bulb, vagina, and uterus were delineated on MR and transferred to CT (rigid registration: penile bulb, deformable registration: vagina and uterus). These registrations were undertaken and validated through visual assessment by an experienced physicist who specializes in MR-CT registrations. The decision to transfer the OARs from MR was made because of the poor visualization of these OARs on CT. All MR TVs and OARs were rigidly transferred to the sCT from the MR to allow radiotherapy treatment planning to occur.

2.3 TV analysis

Volumetric and positional TV analyses were undertaken. The positional analysis compared the overlap of CT and MR volumes using sensitivity and specificity
measures—the volume overlap between CT and MR contours, as a percentage of the volume of CT (sensitivity) or MR (specificity) respectively.

### 2.4 Radiotherapy treatment planning

VMAT plans were created and optimized for each patient’s CT and sCT scan independently by a single experienced clinical scientist following the center’s clinical protocol. Plans were optimized for the delineated TVs and OARs, in Raystation 8b, using the collapsed cone photon algorithm on a dose grid of 3 × 3 × 3 mm³ and beam arrangements seen in Appendix A, Table A3. Rectum plans were prescribed as 45 Gy in 25 fractions to the primary PTV, and anus plans were prescribed a three dose level technique with 53.2 Gy, 50.4 Gy, and 40.0 Gy in 28 fractions to the primary, nodal, and elective PTVs, respectively (subsequently referred to as “standard” plans). To increase the homogeneity of prescription doses, we opted to standardize the dose prescription for each cancer site (in practice some patients received 25 Gy in 5 for rectal cancers and 50.4 Gy for T1/2N0 anal cancers).

Dose escalation plans (“Boost” plans) were also generated to assess the impact of dose escalation to GTV-based (“GTVBoost”) structures with 61.6 Gy and 55 Gy prescribed for anus and rectum, respectively. GTVBoost prescription doses were chosen according to clinical trials assessing GTV dose escalation. Boost plans were created by copying each standard plan, adding optimization constraints and objectives for the GTVBoost contour and re-optimizing the plan. All treatment plan optimization parameters and clinical objectives can be seen in Appendix A, Tables A4 and A5.

All plans were optimized to meet target coverage constraints while minimizing OAR doses. The planning protocol was adapted to include a high mandatory coverage goal for all PTVs, with the rationale that high target coverage prevents subjective, plan specific, local areas of poor PTV coverage within the plan objectives which may impact OAR dose reductions.

### 2.5 VMAT plan analysis

As all plans had strict TV coverage criteria, plan assessment focussed on the dosimetric differences to OARs when TV coverage was achieved. Each OAR was assessed in terms of the Vx (%), the volume of the organ as a percentage of the total organ volume, receiving x Gy in dose. DVH statistics were collected for 95%, 90%, 80%, 70%, and 60% of the prescription dose for each standard plan and compared between CT and MR. These dose levels were chosen to allow a more comprehensive analysis of the dose-volume relationship for each OAR. Dose levels lower than 60% of the prescription dose were not assessed. For boost plans, DVH assessments focussed on the dose levels introduced by the GTVboost prescription (52.25 Gy, 49.5 Gy, and 45 Gy [rectum] and 58.5 Gy, 55.4 Gy, and 53.2 Gy [anus]).

For standard and boost plans, collected DVH statistics were filtered such that if both the CT and MR DVH statistic (Vx) were ≤ 1% then the statistic was removed from the analysis. This removed cases where the TV and OAR were separated sufficiently that the OAR was not receiving that dose level on either plan. In all cases, the femoral heads received a dose less than 60% of the prescription and consequently were removed from the analysis.

### 2.6 Statistical analysis

Linear mixed effects (LME) models in STATA were applied to TV volume and OAR dose analyses to establish statistically significant differences in TVs and OAR doses attributable to the change in modality, CT, and MR. Separate models were applied to each cancer site cohort (anus and rectum) and TV/OAR dose level individually. DVH statistic differences were only modeled if five or more patient’s results were present. TV LME models used volume (cc) as the dependant variable, modality (CT and MR), sex (male and female), and staging (1, 2, 3, or 4) as fixed effects independent variables. The OAR dose LME models used DVH statistic, Vx, as the dependant variable, modality (CT and MR), sex (male and female), and organ volume as fixed effect independent variables. Patient was a random effect independent variable in all models. Organ volume was included to account for impact of variations in organ volume (for example the bladder) on the DVH statistics.

### 3 RESULTS

TV comparisons for both anal and rectal cancers found a statistically significant systematic reduction in MR GTV (12.6 cc and 43.6 cc respectively), primary PTV (98.1 cc and 109.1 cc respectively), and GTVBoost (22.3 cc and 95.2 cc respectively) volumes compared to CT. Table 2 shows the MR TV volume differences versus CT, their statistical significances and the positional overlap between MR and CT. Figure 1 shows a visual example of the changes in GTV, CTVA, and primary PTV between MR and CT for a single anus and rectum cancer case. Figure 2 shows box plots of the volumes of the anal and rectal radiotherapy TVs on CT an MR.

For anus plans, statistically significant dosimetric reductions were found on MR (vs. CT) plans for the bladder (3.8%), penile bulb (~10%), and genitalia (~4%). Systematic dose reductions that had not reached statistical significance were also found for the vagina (~13%). For rectum plans, statistically significant dosimetric reductions were found on MR (vs. CT) plans for
TABLE 2 The magnetic resonance (MR) target volume (TV) differences in volume compared to computed tomography (CT) and the mean sensitivity and specificity overlap for each target volume between MR and CT over the whole patient cohort, where effect size is the systematic difference between MR and CT volumes (a negative value indicates that MR is smaller than CT). Bold effect size values indicate statistically significant confidence intervals.

|                | MR volume effect size versus CT (95% confidence intervals) (cc) | MR volume effect size versus CT (%) | Mean overlap |
|----------------|---------------------------------------------------------------|------------------------------------|--------------|
|                |                                                               |                                    |              |
| Rectum         |                                                               |                                    |              |
| GTV            | −43.6 (−54.8 to −32.5)                                       | −56.5                              | 36.4         |
| CTVA           | −95.2 (−116.3 to −74.3)                                      | −37.1                              | 57.8         |
| CTVB           | −11.7 (−17.1 to −6.3)                                         | −2.6                               | 94.5         |
| CTVF           | −66.0 (−80.7 to −51.4)                                        | −12.4                              | 85.7         |
| PTVA           | −109.1 (−131.1 to −87.2)                                      | −8.6                               | 90.3         |
| GTVBoost       | −95.2 (−116.3 to −74.3)                                       | −28.2                              | 57.8         |
| Anus           |                                                               |                                    |              |
| GTV            | −12.6 (−19.5 to −5.7)                                         | −46.6                              | 32.5         |
| CTVA           | −47.7 (−72.4 to −22.9)                                        | −20.7                              | 66.0         |
| PTVA           | −98.1 (−146.1 to −50.1)                                       | −19.3                              | 72.4         |
| GTVN           | −3.0 (−7.6 to 1.5)                                            | −15.7                              | 53.5         |
| CTVN           | −9.2 (−20.3 to 1.9)                                           | −12.5                              | 70.7         |
| PTVN           | −24.5 (−47.0 to −2.1)                                         | −16.5                              | 74.4         |
| CTVE-all       | −35.0 (−56.6 to −13.4)                                        | −4.0                               | 89.8         |
| PTVE-all       | −106.8 (−144.7 to −68.9)                                      | −5.9                               | 88.1         |
| GTVBoost       | −22.3 (−33.7 to −10.9)                                        | −34.4                              | 46.9         |

Abbreviations: CTVA, primary clinical target volume; CTVB/E, elective clinical target volume; CTVF, final clinical target volume; CTVN, nodal clinical target volume; GTV, gross tumor volume; GTVBoost, boost gross tumor volume; GTVN, nodal gross tumor volume; PTV/PTVA, primary planning target volume; PTVE, elective planning target volume; PTVN, nodal planning target volume.

FIGURE 1 Comparison of anus (right) and rectum (left) cancer GTVs (red), CTVAs (orange), and primary PTVs (blue) for MR (bold) versus CT (dotted) delineations on CT (top) and T2 SPACE MR (bottom) datasets.

the bladder (~5%) and uterus (~13%). Systematic dose reductions that had not reached statistical significance were found for the penile bulb (~6%). Table 3 shows the dosimetric differences to OARs in standard plans between MR and CT.

For rectum boost plans, statistically significant dosimetric reductions were found for the bladder (4.6%), small bowel (~3.5%), sigmoid (~5%), vagina (13.6%), uterus (~20%), and penile bulb (11.5%). For anus plans, statistically significant dosimetric reductions were found for the vagina (4.4%) and penile bulb (15.4%). Table 4 shows the dosimetric differences to organs in boost plans between CT and MR.

4 DISCUSSION

A challenge to wide-spread adoption of MR-only radiotherapy treatment planning is the lack of evidence within the literature demonstrating its benefit in terms of improving treatments. Here, we provide evidence that utilizing an MR-only radiotherapy pathway for anal and rectal cancers makes statistically significant changes to TV volumes and treatment plan OAR doses, in terms of reductions in volume (~100 cc for PTV/PTVA) and dose-volume (5%–20%) compared to a CT-only pathway. These TV and treatment plan changes can be
FIGURE 2  Box-plots comparing the volumes of treatment target volumes for anal cancers (top left), rectal cancers (top right), and all GTVs (bottom middle) on CT (dark grey) and MR (light grey) including the median, interquartile range, and outlier values.

Considered evidence of benefit as smaller TVs result in less irradiated tissue, and lower normal tissue doses can be expected to lead to reduced organ toxicities.\textsuperscript{18} It is important to recognize that while we have compared an MR-only radiotherapy pathway to a CT-only pathway, many centers with radiotherapy MR provision employ a CT-MR pathway. Our findings are more difficult to apply to CT-MR pathways which, compared to MR-only, introduce co-registration errors. As such the treatment changes, we present here would likely be smaller for a
CT-MR pathway. However, our findings can also broadly be applied to MR-CT pathways and therefore add to a growing body of evidence that the introduction of MR can improve treatments, whether through MR-only or CT-MR pathways, which has not previously been shown in the literature in these terms.

Our findings showed that the improved soft tissue visualization of MR translated into reduced TV volumes for both anal and rectal cancers. GTV volumes were reduced significantly as suggested by diagnostic CT visualization of MR translated into reduced TV volumes. The

| Standard Plans | Dose level | Anus Number of patients | Vx effect size (95% confidence intervals) (%) | Rectum Number of patients | Vx effect size (95% confidence intervals) (%) |
|---------------|-----------|-------------------------|---------------------------------------------|---------------------------|---------------------------------------------|
| Bladder       | V95%      | 7                       | -0.6 (−5.6 to 4.4)                          | 28                        | −5.3 (−8.2 to −2.4)                         |
|               | V90%      | 5                       | −1.5 (−6.5 to 3.5)                          | 29                        | −3.0 (−7.1 to 1.1)                          |
|               | V80%      | 17                      | −2.7 (−9.6 to 4.3)                          | 17                        | −0.6 (−5.7 to 4.5)                          |
|               | V70%      | 17                      | −2.5 (−11.1 to 6.0)                         | 23                        | −1.0 (−5.7 to 3.7)                          |
|               | V60%      | 14                      | 5.0 (−0.7 to 10.7)                          | 23                        | −0.8 (−6.7 to 5.0)                          |
| Small bowel   | V95%      | 0                       | −                                  | 23                        | −1.0 (−5.4 to 3.4)                          |
|               | V90%      | 1                       | −                                  | 23                        | −0.9 (−5.6 to 3.7)                          |
|               | V80%      | 3                       | −                                  | 23                        | −0.9 (−5.6 to 3.7)                          |
|               | V70%      | 13                      | 2.0 (−2.0 to 5.9)                         | 23                        | −0.8 (−6.1 to 4.4)                          |
|               | V60%      | 14                      | 5.0 (−0.7 to 10.7)                        | 23                        | −0.8 (−6.7 to 5.0)                          |
| Sigmoid       | V95%      | 2                       | −                                  | 29                        | −1.0 (−7.1 to 1.1)                          |
|               | V90%      | 3                       | −                                  | 29                        | −2.7 (−6.9 to 1.5)                          |
|               | V80%      | 5                       | −1.5 (−6.5 to 3.5)                        | 29                        | −1.8 (−6.3 to 2.7)                          |
|               | V70%      | 17                      | −2.7 (−9.6 to 4.3)                        | 29                        | −1.0 (−5.7 to 3.7)                          |
|               | V60%      | 17                      | −2.5 (−11.1 to 6.0)                       | 29                        | −0.6 (−5.7 to 4.5)                          |
| Vagina        | V95%      | 8                       | −12.5 (−29.2 to 4.2)                      | 14                        | 0.7 (−1.3 to 2.6)                           |
|               | V90%      | 8                       | −12.9 (−28.9 to 3.2)                      | 14                        | 0.5 (−1.3 to 2.3)                           |
|               | V80%      | 8                       | −16.0 (−33.4 to 1.4)                      | 14                        | 0.1 (−1.3 to 1.6)                           |
|               | V70%      | 8                       | −3.5 (−7.7 to 0.7)                        | 14                        | 0.2 (−1.1 to 1.5)                           |
|               | V60%      | 8                       | 1.1 (−0.5 to 2.7)                         | 14                        | 0.7 (−0.7 to 2.1)                           |
| Uterus        | V95%      | 2                       | −                                  | 13                        | −15.9 (−24.4 to −7.4)                       |
|               | V90%      | 2                       | −                                  | 13                        | −14.9 (−23.8 to −6.1)                       |
|               | V80%      | 3                       | −                                  | 13                        | −13.8 (−22.6 to −4.9)                       |
|               | V70%      | 7                       | −10.4 (−27.3 to 6.6)                      | 13                        | −12.8 (−21.3 to −4.3)                       |
|               | V60%      | 7                       | 2.6 (−24.3 to 29.6)                      | 13                        | −11.8 (−20.3 to −3.2)                       |
| Penile Bulb   | V95%      | 9                       | −11.2 (19.9 to −2.5)                      | 6                         | −7.3 (−27.2 to 12.5)                        |
|               | V90%      | 9                       | −9.6 (−16.4 to −2.7)                      | 9                         | −5.4 (−18.4 to 7.6)                         |
|               | V80%      | 9                       | −8.3 (−15.5 to −1.2)                      | 9                         | −6.0 (−18.2 to 6.2)                         |
|               | V70%      | 9                       | −8.4 (−16.2 to −0.7)                      | 9                         | −7.3 (−18.8 to 4.2)                         |
|               | V60%      | 9                       | −8.8 (−16.8 to −0.7)                      | 10                        | −9.7 (−21.5 to 2.1)                         |
| Genitalia     | V95%      | 5                       | −4.8 (−11.0 to 1.3)                       | −                         | −9.7 (−21.5 to 2.1)                         |
|               | V90%      | 5                       | −5.2 (−12.0 to 1.6)                       | −                         | −9.7 (−21.5 to 2.1)                         |
|               | V80%      | 6                       | −5.1 (−11.5 to 1.3)                       | −                         | −9.7 (−21.5 to 2.1)                         |
|               | V70%      | 11                      | −4.0 (−7.5 to −0.5)                       | −                         | −9.7 (−21.5 to 2.1)                         |
|               | V60%      | 17                      | −3.5 (−5.7 to −1.3)                       | −                         | −9.7 (−21.5 to 2.1)                         |

TABLE 3 The magnetic resonance (MR) dosimetric differences to organs at risks (OARs) in standard plans for anal and rectal cancer treatments, where volume effect size is the systematic difference in volume of each organ receiving x Gy of dose on MR versus computed tomography (CT) (a negative value indicated a lower dose on MR compared to CT). Bold effect size values indicate statistically significant confidence intervals. “Number of patients” is the number of patients whose DVH statistics were >1% on both CT and MR and therefore included in the analysis.
TABLE 4 The MR dosimetric differences to organs at risks (OARs) in boost plans for anal and rectal cancer treatments, where volume effect size is the systematic difference in volume of each organ receiving x Gy of dose on magnetic resonance (MR) versus computed tomography (CT) (a negative value indicated a lower dose on MR compared to CT). Bold effect size values indicate statistically significant confidence intervals. “Number of patients” is the number of patients whose dose-volume histogram (DVH) statistics were <1% on both CT and MR and therefore included in the analysis.

| Boost Plans | Anus | Rectum |
|-------------|------|--------|
| Dose level  | Number of patients | Vx Effect size (95% confidence intervals) (%) | Dose level  | Number of patients | Vx effect size (95% confidence intervals) (%) |
| Bladder     | V55.4 0             | –                   | V49.5 11           | –3.0 (−6.1 to 0.1) |
|             | V53.2 2             | –                   | V45 27             | −4.6 (−7.6 to −1.7) |
| Small bowel | V58.5 0             | –                   | V52.25 8           | −3.4 (5.9 to −0.8) |
|             | V55.4 0             | –                   | V49.5 8            | −3.6 (−6.7 to −0.5) |
|             | V53.2 0             | –                   | V45 23             | −1.0 (−3.9 to 1.9) |
| Sigmoid     | V58.5 0             | –                   | V52.25 16          | −6.4 (−9.1 to −3.7) |
|             | V55.4 0             | –                   | V49.5 16           | −6.4 (−9.6 to −3.3) |
|             | V53.2 1             | –                   | V45 29             | −4.6 (8.9 to −0.4) |
| Vagia       | V58.5 7             | −4.4 (−8.0 to −0.8) | V52.25 13          | −13.6 (−26.3 to −0.9) |
|             | V55.4 7             | −8.7 (−22.0 to 4.7) | V49.5 14           | −6.9 (−17.1 to 3.2) |
|             | V53.2 8             | −11.1 (−28.3 to 6.0) | V45 14             | −1.7 (−5.7 to 2.2) |
| Uterus      | V58.5 0             | –                   | V52.25 11          | −19.8 (−30.7 to −9.0) |
|             | V55.4 1             | –                   | V49.5 12           | −21.9 (−32.7 to −11.2) |
|             | V53.2 2             | –                   | V45 13             | −19.6 (−26.9 to −12.3) |
| Penile Bulb | V58.5 3             | –                   | V52.25 3           | – |
|             | V55.4 7             | −22.4 (−49.2 to 4.4) | V49.5 4            | – |
|             | V53.2 8             | −15.4 (−30.3 to −0.5) | V45 6             | −11.5 (−34.3 to −11.3) |
| Genitalia   | V58.5 2             | –                   | –                 | – |
|             | V55.4 3             | –                   | –                 | – |
|             | V53.2 4             | –                   | –                 | – |

resultant ~100 cc reduction in PTV volume is a significant amount of tissue which will be spared a high (prescription level) dose. Both cancer sites also saw significant reductions in anatomically defined CTVB/E volumes from CT to MR. A visual assessment of the CTVs showed that this was due to an improvement in tissue visualization at the mesorectum anterior border, where it is difficult to define the mesorectum, vagina, and seminal vesicles borders on CT. This soft-tissue contrast improvement has the potential to also improve clinician confidence, speed, and inter-observer variability when delineating, although assessing this was beyond the scope of this study. The GTVBoost volume reductions also add evidence that MR-based radiotherapy treatment planning may have a greater impact on boost plans. Our positional differences between MR and CT delineated TVs showed the specificity of TVs (overlap as a percentage of the MR volume) was much higher than the sensitivity (overlap as a percentage of the CT volume), suggesting that MR volumes are not only smaller than CT, but also predominantly within the CT volumes which adds strength to the hypothesis that MR improves the visualization of TVs. It is notable that our delineation protocol for rectum GTVs varied between CT and MR, where CT GTVs included the whole lumen but MR GTVs included the visible tumor only. This was due to the soft tissue contrast of MR enabling a systematic change in delineation protocol through improved visualization, and it is the impact of this improved visualization that we have quantified here.

Our standard treatment plan analysis found statistically significant reductions in OAR doses for both cancer sites. This provides evidence that MR-only radiotherapy treatment planning makes a quantitatively significant improvement to treatment plans compared to CT-only pathways. The OAR dose changes that we saw here are logical. For standard plans we saw that the organs closest to the primary GTV—the sexual organs for anal cancers,19 and the bladder and uterus for rectum cancers had statistically significant systematic dose reductions, whereas we saw no change to the small bowel dose which is predominantly the organ furthest from the GTV. There were also a number of organs that had systematic dose reductions that had not reached statistical significance. While less definitive, these findings should also be viewed positively and
suggest that there may be additional benefit in a larger population. Our dose escalation (boost) plan analysis also suggests that MR boost plans were able to improve the sparing of OARs very close to the primary GTV, for example the vagina and penile bulb for anal cancers, but that for rectal cancers there was a much wider dose reduction to the majority of OARs, including small bowel and sigmoid. This can be explained by the much larger GTVBoost volume for rectal cancers compared to anal cancers, the central position of the rectum in the pelvic cavity, and the differences in the elective CTV standard plan dose prescription between rectal and anal cancers.

There are limitations to this study. It is known that some tumor shrinkage occurs during treatment as shown by Van den Begin\textsuperscript{20} who found for rectal cancers some tumor shrinkage during treatment as plan dose prescription between rectal and anal cancers. There is also an argument that reducing TVs due to a change in imaging modality could have a negative effect on tumor control probability as our understanding of required treatment dose levels stems from CT-based targets and the reduction of the TVs is in essence removing implicit margins caused by a lack of contrast on CT. This argument highlights the need for caution when assessing new techniques such as MR-only planning.

Our findings suggest that MR-only radiotherapy treatment planning can be considered to be an improvement in the personalization of radiotherapy treatments, compared to CT-only, as it allows clearer visualization of individual patient anatomy. Here, we aimed to assess the impact of MR-only radiotherapy treatment planning on TVs and treatment plan doses to OARs for anal and rectal cancers when compared to a routine CT-only pathway. Our findings provide evidence that MR-only radiotherapy treatment planning for anal and rectal cancers results in statistically significant reductions in TV volumes and reduced doses to a number of OARs. This suggests that patients could benefit from MR-only (or CT-MR) radiotherapy treatment planning with the potential for improved patient outcomes if OAR dose reductions translate into less treatment-related toxicity or support GTV dose escalation.

ACKNOWLEDGMENTS

The assistance with data collection and transfer from the following was greatly appreciated: radiotherapy CT and diagnostic MR radiographers, physicists; Dan Wilson, David Broadbent, Sarah Wright, research radiographers; Pam Shuttleworth and Louise Loughman and clinical oncologists; Paul Hatfield, Michelle Kwok-Williams and Mohan Hingorani. Statistical advice was provided by Sarah Brown and Eleanor Hudson at Leeds CTRU. Mr David Bird is funded by a National Institute for Health Research (NIHR) Clinical Doctoral Research Fellowship for this research. Dr Michael G. Nix is supported by the Sir John Fisher Foundation, CRUK Radnet and an NHS Topol Fellowship. Dr Richard Speight is supported by a Cancer Research UK Centres Network Accelerator Award Grant (A21993) to the ART-NET consortium. This publication presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
REFERENCES

1. Bird D, Henry AM, Sebag-Montefiore D, Buckley DL, Al-Qaisieh B, Speight R. A systematic review of the clinical implementation of pelvic magnetic resonance imaging–only planning for external beam radiation therapy. *Int J Radiat Oncol Biol Phys.* 2019;105(3):479-492.

2. Johnstone E, Wyatt JJ, Henry AM, et al. Systematic review of synthetic computed tomography generation methodologies for use in magnetic resonance imaging–only radiation therapy. *Int J Radiat Oncol Biol Phys.* 2018;100(1):199-117.

3. Edmund JM, Nyholm T. A review of substitute CT generation for MRI-only radiation therapy. *Radiat Oncol.* 2017;12(1).

4. Tenhunen M, Korhonen J, Kapanen MJ, et al. MRI-only based radiation therapy of prostate cancer: workflow and early clinical experience. *Acta Oncol (Madr).* 2018;57(7):902-907.

5. Speight R, Schmidt MA, Liney GP, et al. IPEM topical report: a 2018 IPEM survey of MRI use for external beam radiotherapy treatment planning in the UK. *Phys Med Biol.* 2019;64(17):175021.

6. Maspero M, Tyyger MD, Tijssen RHN, Seevinck PR, Intven MPW, van den Berg CAT. Feasibility of magnetic resonance imaging-only rectum radiotherapy with a commercial synthetic computed tomography generation solution. *Phys Imaging Radiat Oncol.* 2018;7:58-64.

7. Owrangi AM, Greer PB, Glide-Hurst CK. MRI-only treatment planning: benefits and challenges. *Phys Med Biol.* 2018;63(5):05TR01.

8. Jonsson J, Nyholm T, Söderkvist K. The rationale for MR-only treatment planning for external radiotherapy. *Clin Transl Radiat Oncol.* 2019;18:60-65.

9. Gwynne S, Mukherjee S, Webster R, et al. Imaging for target volume delineation in rectal cancer radiotherapy - a systematic review. *Clin Oncol.* 2012;24(1):52-63.

10. Serup-Hansen E, Hendel HW, Johannesen HH, et al. Variation in gross tumor volume delineation using CT, MRI, and FDG-PET in planning radiotherapy of anal cancer. *J Clin Oncol.* 2012;30:652-652.

11. Schmidt MA, Payne GS. Radiotherapy planning using MRI. *Phys Med Biol.* 2015;60(22):R323-61.

12. Dean CJ, Sykes JR, Cooper RA, et al. An evaluation of four CT–MRI co-registration techniques for radiotherapy treatment planning of prone rectal cancer patients. *Br J Radiol.* 2012;85(1009):61-68.

13. Yamashita H, Ishihara S, Nozawa H, et al. Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis. *Radiat Oncol.* 2017;12(1):156.

14. Sebag-Montefiore D, Adams R, Bell S, et al. The development of an umbrella trial (PLATO) to address radiation therapy dose questions in the locoregional management of squamous cell carcinoma of the anus. *Int J Radiat Oncol.* 2016;96(2):E164-E165.

15. Owens R, Mukherjee S, Padmanaban S, et al. Intensity-modulated radiotherapy with a simultaneous integrated boost in rectal cancer. *Clin Oncol.* 2020;32(1):35-42.

16. Bird D, Nix MG, McCallum H, et al. Multicentre, deep learning, synthetic-CT generation for ano-rectal MR-only radiotherapy treatment planning. *Radiother Oncol.* 2021;156:23-28.

17. How to cite this article: Bird D, Nix MG, McCallum H, et al. The benefit of MR-only radiotherapy treatment planning for anal and rectal cancers: A planning study. *J Appl Clin Med Phys.* 2021;22(11):41–53. https://doi.org/10.1002/acm2.13423
APPENDIX A

### TABLE A1 Anal and rectal cancer patient demographics

| Age          | Mean (range) | Anus (total 17) | Rectum (total 29) |
|--------------|--------------|-----------------|-------------------|
| Sex          |              | 63 (47–76)      | 63 (38–78)        |
| Male         | 9            | 15              |
| Female       | 8            | 14              |
| Staging      |              |                 |                   |
| T1           | 2            | 1               |
| T2           | 5            | 11              |
| T3           | 9            | 16              |
| T4           | 1            | 1               |
| MR scan acquired |          |                 |                   |
| Pretreatment | 6            | 13              |
| Fraction 1–5 | 4            | 9               |
| Fraction 6–10| 6            | 6               |
| Fraction 11–13| 1           | 1               |

### TABLE A2 computed tomography (CT) and magnetic resonance (MR) simulation scan parameters

| MR Make & Model | Siemens Aera 1.5 T |
|-----------------|-------------------|
| Sequence        | 3D                |
| Resolution      | 0.9 × 0.9 × 1.5 mm|
| Refocusing flip angle (°) | 160 |
| TR (ms)         | 1600              |
| TE (ms)         | 211               |
| Bandwidth (Hz/px) | 545            |
| Echo train length | 134             |
| Field of view (superior-inferior) | Inferior: 2 cm inferior of genitalia Superior: superior aspect of L5 vertebra or greater as required |
| Field of view (Axial) | 450 × 450 mm² |

| CT Make & Model | Philips Brilliance Big Bore |
|-----------------|----------------------------|
| Resolution      | 1.2 × 1.2 × 2 mm           |
| kVp (kV)        | 120                        |
| X-ray tube current (mAs) | 135            |

### TABLE A3 Treatment plan beam arrangement and prescription parameters for standard plans

| Anus | Rectum |
|------|--------|
| Modality | Photons |
| Technique | VMAT |
| Prescription type | “Average Dose” |
| Isocenter Position | Center of PTV |
| Energy (MV) | 6MV FFF |
| Beam arrangement | 360° arc (starting at 180°) |
| Beam optimization settings | Dual arc |
| PTV Standard Plan Prescription | 53.2 Gy in 28 fractions 45 Gy in 25 fractions |
| PTVN | 50.4 Gy in 28 fractions X |
| PTVE | 40 Gy in 28 fractions X |
| GTVBoost | X |
| Boost plan additional prescription | 61.6 Gy in 28 fractions 55 Gy in 25 fractions |

Abbreviations: GTVBoost, boost gross tumor volume; PTV, primary planning target volume; PTVE, elective planning target volume; PTVN, nodal planning target volume; VMAT, volumetric arc therapy.
TABLE A4  Treatment plan initial optimization parameters for standard and boost plans for anal and rectal cancers

| Optimization objectives | Target volume/OAR | Objective | Description | Target volume/OAR | Objective | Description |
|-------------------------|-------------------|-----------|-------------|-------------------|-----------|-------------|
| **Rectum**              |                   |           |             |                   |           |             |
| Standard plan           | PTV               | Min dose  | 45 Gy       | PTV               | Min dose  | 53.2 Gy     |
|                         |                   | Uniform dose | 45 Gy |                   | Uniform dose | 53.2 Gy |
|                         | Patient external  | Dose fall off | High: 45 Gy, | Dose fall off | High: 53.2 Gy, | |
|                         |                   |           | Low: 25 Gy, |           | Low: 25 Gy, | |
|                         |                   |           | Distance: 1.5 cm |           | Distance: 1.5 cm | |
|                         | Bladder-PTV       | Max DVH  | 20.0 Gy to 30% | Dose fall off | High: 53.2 Gy, | |
|                         |                   |           |             |           | Low: 50.4 Gy, | |
|                         |                   |           |             |           | Distance: 2.0 cm | |
|                         | Bowel cavity -PTV | Max DVH  | 20.0 Gy to 30% | PTVE - (PTV+PTVN) | Min dose  | 40 Gy |
|                         | Penile bulb - PTV | Max DVH  | 20 Gy to 35% | Dose fall off | High: 53.2 Gy, | |
|                         |                   |           |             |           | Low: 40.0 Gy, | |
|                         |                   |           |             |           | Distance: 2.0 cm | |
|                         | Uterus - PTV      | Max DVH  | 20 Gy to 35% | Patient external | Dose fall off | High: 53.2 Gy, | |
|                         |                   |           |             |           | Low: 25 Gy, | |
|                         |                   |           |             |           | Distance: 1.5 cm | |
|                         | Vagina - PTV      | Max DVH  | 20 Gy to 35% | Dose fall off | High: 53.2 Gy, | |
|                         |                   |           |             |           | Low: 0 Gy, | |
|                         |                   |           |             |           | Distance: 6.0 cm | |
|                         | X                 |           |             | Bladder - PTVs | Max DVH | 20 Gy to 35% |
|                         |                   |           |             | Small bowel - PTVs | Max DVH | 20 Gy to 35% |
|                         |                   |           |             | Femoral heads - PTVs | Max DVH | 20 Gy to 35% |
|                         |                   |           |             | Genitalia - PTVs | Max DVH | 20 Gy to 35% |
|                         |                   |           |             | Penile bulb - PTVs | Max DVH | 20 Gy to 35% |
|                         |                   |           |             | Uterus - PTVs | Max DVH | 20 Gy to 35% |
|                         |                   |           |             | Vagina - PTVs | Max DVH | 20 Gy to 35% |
| Boost plan objectives   | GTVBoost          | Min dose  | 55.0 Gy     | GTVBoost         | Min dose  | 61.6 Gy     |
|                         |                   | Uniform dose | 55.0 Gy |                   | Uniform dose | 61.6 Gy |
|                         | PTV               | Dose fall off | High: 55.0 Gy, | PTV              | Dose fall off | High: 61.6 Gy, | |
|                         |                   |           | Low: 45.0 Gy, |           | Low: 53.2 Gy, | |
|                         |                   |           | Distance: 1.0 cm |           | Distance: 1.0 cm | |

Abbreviations: GTVBoost, boost gross tumor volume; PTV, primary planning target volume; PTVE, elective planning target volume; PTVN, nodal planning target volume.
### TABLE A5  Treatment plan clinical objectives for standard and boost plans for anal and rectal cancers

| Clinical objectives | Rectum | Anus |
|---------------------|--------|------|
| **Target volume/OAR** | **Objective** | **Goal** | **Target volume/OAR** | **Objective** | **Goal** |
| **Standard plan** | | |
| PTV | V42.75 Gy (95%) | >99.5% | PTV | D99.5% | ≥95% (50.54 Gy) |
| | V47.25 Gy (105%) | <0.1% | | D50% | ≥99% (52.6 Gy) and ≤101% (53.7 Gy) |
| | D50% | ≥99% (44.55 Gy) and <101% (45.45 Gy) | | D1% | ≤105% (55.9 Gy) |
| Bowel cavity | V20Gy | <400 cc | PTVN – PTV | D99.5% | ≥95% (47.9 Gy) |
| | V30Gy | <250 cc | | D50% | ≤105% (55.9 Gy) |
| | V43Gy | <200 cc | PTVE – (PTV+ PTVN) | D99.5% | ≥95% (38.0 Gy) |
| Bladder | V35Gy | <45% | Small bowel | D200cc | ≤35 Gy |
| | | | | D150cc | ≤40 Gy |
| | | | | D20cc | ≤50 Gy |
| | | | | D5cc | ≤55 Gy |
| X | | | Bladder | D50% | ≤45 Gy |
| | | | | D35% | ≤50 Gy |
| | | | | D5% | ≤55 Gy |
| | | | Femoral heads | D50% | ≤45 Gy |
| | | | | D35% | ≤50 Gy |
| | | | | D5% | ≤55 Gy |
| | | | Genitalia | D50% | ≤35 Gy |
| | | | | D35% | ≤40 Gy |
| | | | | D5% | ≤55 Gy |
| Boost plan objectives | GTVBoost | V52.25 Gy (95%) | >99.5% | GTVBoost | D99.5% | ≥95% (58.1 Gy) |
| | | V52.25 Gy (105%) | <0.1% | | D50% | ≥99% (61.0 Gy) and ≤101% (62.2 Gy) |

Abbreviations: GTVBoost, boost gross tumor volume; PTV, primary planning target volume; PTVE, elective planning target volume; PTVN, nodal planning target volume.

### TABLE A6  Organ volumes on computed tomography (CT) and magnetic resonance (MR) for anal and rectal cancer patients including: Mean (range, SD)

| Organ | CT (cc) | MR (cc) | Difference (cc) |
|-------|---------|---------|-----------------|
| **Rectum** | | | |
| Bladder | 275 (48–962, 170) | 305 (32–746, 167) | 30 (−266–458, 169) |
| Sigmoid | 108 (23–309, 76) | 92 (10–310, 77) | −16 (−126–28, 34) |
| Small bowel | 264 (0–741, 179) | 225 (0–659, 148) | −30 (−406–202, 125) |
| Penile bulb | 6 (2–11, 2) | 6 (2–11, 2) | 0 (0, 0) |
| Vagina | 18 (9–41, 9) | 15 (8–31, 7) | −3 (−10–1, 3) |
| Uterus | 61 (9–116, 31) | 57 (22–108, 28) | −4 (−20–15, 10) |
| **Anus** | | | |
| Bladder | 318 (95–813, 186) | 324 (44–891, 202) | 6 (−180–322, 13) |
| Sigmoid | 156 (36–381, 97) | 127 (14–366, 84) | −29 (−99–61, 43) |
| Small bowel | 284 (27–818, 212) | 212 (50–527, 143) | −72 (−292–136, 109) |
| Penile bulb | 5 (2–11, 3) | 5 (2–11, 3) | 0 (0, 0) |
| Vagina | 13 (8–25, 6) | 12 (5–18, 5) | −2 (−7–2, 3) |
| Uterus | 34 (13–64, 16) | 31 (14–55, 12.5) | −3 (−9–6, 5) |
| Genitalia | 298 (58–686, 181) | 297 (56.8–686, 181) | 0 (0, 0) |